|
1
|
Ogura K, Higashi T and Kawai A: Statistics
of bone sarcoma in Japan: Report from the bone and soft tissue
tumor registry in Japan. J Orthop Sci. 22:755–764. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Meyers PA, Schwartz CL, Krailo MD, Healey
JH, Bernstein ML, Betcher D, Ferguson WS, Gebhardt MC, Goorin AM,
Harris M, et al: Osteosarcoma: The addition of muramyl tripeptide
to chemotherapy improves overall survival-A report from the
childrens oncology group. J Clin Oncol. 26:633–638. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bielack SS, Kempf-Bielack B, Delling G,
Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M,
Winkelmann W, et al: Prognostic factors in high-grade osteosarcoma
of the extremities or trunk: An analysis of 1,702 patients treated
on neoadjuvant cooperative osteosarcoma study group protocols. J
Clin Oncol. 20:776–790. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Picci P, Sangiorgi L, Rougraff BT, Neff
JR, Casadei R and Campanacci M: Relationship of
chemotherapy-induced necrosis and surgical margins to local
recurrence in osteosarcoma. J Clin Oncol. 12:2699–2705. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ferrari S, Ruggieri P, Cefalo G, Tamburini
A, Capanna R, Fagioli F, Comandone A, Bertulli R, Bisogno G,
Palmerini E, et al: Neoadjuvant chemotherapy with methotrexate,
cisplatin, and doxorubicin with or without ifosfamide in
nonmetastatic osteosarcoma of the extremity: An Italian sarcoma
group trial ISG/OS-1. J Clin Oncol. 30:2112–2118. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Borys D, Canter RJ, Hoch B, Martinez SR,
Tamurian RM, Murphy B, Bishop JW and Horvai A: P16 expression
predicts necrotic response among patients with osteosarcoma
receiving neoadjuvant chemotherapy. Hum Pathol. 43:1948–1954. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sadikovic B, Thorner P, Chilton-Macneill
S, Martin JW, Cervigne NK, Squire J and Zielenska M: Expression
analysis of genes associated with human osteosarcoma tumors shows
correlation of RUNX2 overexpression with poor response to
chemotherapy. BMC Cancer. 10:2022010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Laverdiere C, Hoang BH, Yang R, Sowers R,
Qin J, Meyers PA, Huvos AG, Healey JH and Gorlick R: Messenger RNA
expression levels of CXCR4 correlate with metastatic behavior and
outcome in patients with osteosarcoma. Clin Cancer Res.
11:2561–2567. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wunder JS, Bull SB, Aneliunas V, Lee PD,
Davis AM, Beauchamp CP, Conrad EU, Grimer RJ, Healey JH, Rock MJ,
et al: MDR1 gene expression and outcome in osteosarcoma: A
prospective, multicenter study. J Clin Oncol. 18:2685–2694. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yan T, Wunder JS, Gokgoz N, Gill M,
Eskandarian S, Parkes RK, Bull SB, Bell RS and Andrulis IL: COPS3
amplification and clinical outcome in osteosarcoma. Cancer.
109:1870–1876. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Man TK, Lu XY, Jaeweon K, Perlaky L,
Harris CP, Shah S, Ladanyi M, Gorlick R, Lau CC and Rao PH:
Genome-wide array comparative genomic hybridization analysis
reveals distinct amplifications in osteosarcoma. BMC Cancer.
4:452004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mintz MB, Sowers R, Brown KM, Hilmer SC,
Mazza B, Huvos AG, Meyers PA, Lafleur B, McDonough WS, Henry MM, et
al: An expression signature classifies chemotherapy-resistant
pediatric osteosarcoma. Cancer Res. 65:1748–1754. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ochi K, Daigo Y, Katagiri T, Nagayama S,
Tsunoda T, Myoui A, Naka N, Araki N, Kudawara I, Ieguchi M, et al:
Prediction of response to neoadjuvant chemotherapy for osteosarcoma
by gene-expression profiles. Int J Oncol. 24:647–655.
2004.PubMed/NCBI
|
|
14
|
Iwamoto Y, Tanaka K, Isu K, Kawai A,
Tatezaki S, Ishii T, Kushida K, Beppu Y, Usui M, Tateishi A, et al:
Multiinstitutional phase II study of neoadjuvant chemotherapy for
osteosarcoma (NECO study) in Japan: NECO-93J and NECO-95J. J Orthop
Sci. 14:397–404. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Moore DD: Preparation and analysis of DNA.
Current protocols in molecular biology. Ausubel FM, Brent R,
Kingston RF, Moore DD, Seidman JG, Smith JA and Struhl K: 1. units
2.2 and 2.4.Greene Publishing Associates/Wiley-Interscience; New
York, NY: 1989
|
|
16
|
Rutledge RG and Côté C: Mathematics of
quantitative kinetic PCR and the application of standard curves.
Nucleic Acids Res. 31:e932003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tatsumi Y, Takano R, Islam MS, Yokochi T,
Itami M, Nakamura Y and Nakagawara A: BMCC1, which is an
interacting partner of BCL2, attenuates AKT activity, accompanied
by apoptosis. Cell Death Dis. 6:e16072015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Link MP, Goorina AM, Horowitz M, Meyer WH,
Belasco J, Baker A, Ayala A and Shuster J: Adjuvant chemotherapy of
high-grade osteosarcoma of the extremity. Updated results of the
multi-institutional osteosarcoma study. Clin Orthop Relat Res.
8–14. 1991.PubMed/NCBI
|
|
19
|
Zhou Y, Shen JK, Yu Z, Hornicek FJ, Kan Q
and Duan Z: Expression and therapeutic implications of
cyclin-dependent kinase 4 (CDK4) in osteosarcoma. Biochim Biophys
Acta Mol Basis Dis. 1864:1573–1582. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kovac M, Blattmann C, Ribi S, Smida J,
Mueller NS, Engert F, Castro-Giner F, Weischenfeldt J, Kovacova M,
Krieg A, et al: Exome sequencing of osteosarcoma reveals mutation
signatures reminiscent of BRCA deficiency. Nat Commun. 6:89402015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Behjati S, Tarpey PS, Haase K, Ye H, Young
MD, Alexandrov LB, Farndon SJ, Collord G, Wedge DC, Martincorena I,
et al: Recurrent mutation of IGF signalling genes and distinct
patterns of genomic rearrangement in osteosarcoma. Nat Commun.
8:159362017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cheng L, Pandya PH, Liu E, Chandra P, Wang
L, Murray ME, Carter J, Ferguson M, Saadatzadeh MR,
Bijangi-Visheshsaraei K, et al: Integration of genomic copy number
variations and chemotherapy-response biomarkers in pediatric
sarcoma. BMC Med Genomics. 12 (Suppl 1):S232019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chiappetta C, Mancini M, Lessi F, Aretini
P, De Gregorio V, Puggioni C, Carletti R, Petrozza V, Civita P,
Franceschi S, et al: Whole-exome analysis in osteosarcoma to
identify a personalized therapy. Oncotarget. 8:80416–80428. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang Q, Lv LY, Li BJ, Zhang J and Wei F:
Investigation of ERCC1 and ERCC2 gene polymorphisms and response to
chemotherapy and overall survival in osteosarcoma. Genet Mol Res.
14:11235–11241. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yu JJ, Lee KB, Mu C, Li Q, Abernathy TV,
Bostick-Bruton F and Reed E: Comparison of two human ovarian
carcinoma cell lines (A2780/CP70 and MCAS) that are equally
resistant to platinum, but differ at codon 118 of the ERCC1 gene.
Int J Oncol. 16:555–560. 2000.PubMed/NCBI
|
|
26
|
Smida J, Baumhoer D, Rosemann M, Walch A,
Bielack S, Poremba C, Remberger K, Korsching E, Scheurlen W,
Dierkes C, et al: Genomic alterations and allelic imbalances are
strong prognostic predictors in osteosarcoma. Clin Cancer Res.
16:4256–4267. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen X, Bahrami A, Pappo A, Easton J,
Dalton J, Hedlund E, Ellison D, Shurtleff S, Wu G, Wei L, et al:
Recurrent somatic structural variations contribute to tumorigenesis
in pediatric osteosarcoma. Cell Rep. 7:104–112. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wei G, Lonardo F, Ueda T, Kim T, Huvos AG,
Healey JH and Ladanyi M: CDK4 gene amplification in osteosarcoma:
Reciprocal relationship with INK4A gene alterations and mapping of
12q13 amplicons. Int J Cancer. 80:199–204. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sandberg AA and Bridge JA: Updates on the
cytogenetics and molecular genetics of bone and soft tissue tumors:
Osteosarcoma and related tumors. Cancer Genet Cytogenet. 145:1–30.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Marina N, Gebhardt M, Teot L and Gorlick
R: Biology and therapeutic advances for pediatric osteosarcoma.
Oncologist. 9:422–441. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Toguchida J, Ishizaki K, Sasaki MS,
Ikenaga M, Sugimoto M, Kotoura Y and Yamamuro T: Chromosomal
reorganization for the expression of recessive mutation of
retinoblastoma susceptibility gene in the development of
osteosarcoma. Cancer Res. 48:3939–3943. 1988.PubMed/NCBI
|
|
32
|
Lau CC, Harris CP, Lu XY, Perlaky L,
Gogineni S, Chintagumpala M, Hicks J, Johnson ME, Davino NA, Huvos
AG, et al: Frequent amplification and rearrangement of chromosomal
bands 6p12-p21 and 17p11.2 in osteosarcoma. Genes Chromosomes
Cancer. 39:11–21. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Martin JW, Chilton-MacNeill S, Koti M, van
Wijnen AJ, Squire JA and Zielenska M: Digital expression profiling
identifies RUNX2, CDC5L, MDM2, RECQL4, and CDK4 as Potential
predictive biomarkers for Neo-adjuvant chemotherapy response in
paediatric osteosarcoma. PLoS One. 9:e958432014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Suehara Y, Alex D, Bowman A, Middha S,
Zehir A, Chakravarty D, Wang L, Jour G, Nafa K, Hayashi T, et al:
Clinical genomic sequencing of pediatric and adult osteosarcoma
reveals distinct molecular subsets with potentially targetable
alterations. Clin Cancer Res. 25:6346–6356. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Toki S, Kobayashi E, Yoshida A, Ogura K,
Wakai S, Yoshimoto S, Yonemori K and Kawai A: A clinical comparison
between dedifferentiated low-grade osteosarcoma and conventional
osteosarcoma. Bone Joint J. 101-B:745–752. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liu Z, Cheng C, Luo X, Xia Q, Zhang Y,
Long X, Jiang Q and Fang W: CDK4 and miR-15a comprise an abnormal
automodulatory feedback loop stimulating the pathogenesis and
inducing chemotherapy resistance in nasopharyngeal carcinoma. BMC
Cancer. 16:2382016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Noel EE, Yeste-Velasco M, Mao X, Perry J,
Kudahetti SC, Li NF, Sharp S, Chaplin T, Xue L, McIntyre A, et al:
The association of CCND1 overexpression and cisplatin resistance in
testicular germ cell tumors and other cancers. Am J Pathol.
176:2607–2615. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Cao Y, Li X, Kong S, Shang S and Qi Y:
CDK4/6 inhibition suppresses tumour growth and enhances the effect
of temozolomide in glioma cells. J Cell Mol Med. 24:5135–5145.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Finn RS, Martin M, Rugo HS, Jones S, Im
SA, Gelmon K, Harbeck N, Lipatov ON, Walshe JM, Moulder S, et al:
Palbociclib and letrozole in advanced breast cancer. N Engl J Med.
375:1925–1936. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Du Q, Guo X, Wang M, Li Y, Sun X and Li Q:
The application and prospect of CDK4/6 inhibitors in malignant
solid tumors. J Hematol Oncol. 13:412020. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Edelman MJ, Redman MW, Albain KS, McGary
EC, Rafique NM, Petro D, Waqar SN, Minichiello K, Miao J,
Papadimitrakopoulou VA, et al: SWOG S1400C (NCT02154490)-A Phase II
Study of palbociclib for previously treated cell cycle gene
alteration-positive patients with stage IV squamous cell lung
cancer (Lung-MAP Substudy). J Thorac Oncol. 14:1853–1859. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Leonard JP, LaCasce AS, Smith MR, Noy A,
Chirieac LR, Rodig SJ, Yu JQ, Vallabhajosula S, Schoder H, English
P, et al: Selective CDK4/6 inhibition with tumor responses by
PD0332991 in patients with mantle cell lymphoma. Blood.
119:4597–4607. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Saâda-bouzid E, Burel-vandenbos F,
Ranchère-vince D, Birtwisle-Peyrottes I, Chetaille B, Bouvier C,
Château MC, Peoch M, Battistella M, Bazin A, et al: Prognostic
value of HMGA2, CDK4, and JUN amplification in well-differentiated
and dedifferentiated liposarcomas. Mod Pathol. 28:1404–1414. 2015.
View Article : Google Scholar
|
|
44
|
Miquelestorena-Standley E, Jourdan ML,
Collin C, Bouvier C, Larousserie F, Aubert S, Gomez-Brouchet A,
Guinebretière JM, Tallegas M, Brulin B, et al: Effect of
decalcification protocols on immunohistochemistry and molecular
analyses of bone samples. Mod Pathol. 33:1505–1517. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kuang Y, Cai J, Li D, Han Q, Cao J and
Wang Z: Repression of Dicer is associated with invasive phenotype
and chemoresistance in ovarian cancer. Oncol Lett. 5:1149–1154.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Tsuchida R, Das B, Yeger H, Koren G,
Shibuya M, Thorner PS, Baruchel S and Malkin D: Cisplatin treatment
increases survival and expansion of a highly tumorigenic
side-population fraction by upregulating VEGF/Flt1 autocrine
signaling. Oncogene. 27:3923–3934. 2008. View Article : Google Scholar : PubMed/NCBI
|
